Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Inhibrx revenue
Inhibrx's revenue is $1.8 million.
What is Inhibrx's revenue?
- Inhibrx's revenue growth from 2019 to 2023 is -80.17%.
- Inhibrx has 80 employees, and the revenue per employee ratio is $22,500.
- Inhibrx's peak quarterly revenue was $5.9M in 2020(q3).
- Inhibrx peak revenue was $12.9M in 2020.
- Inhibrx annual revenue for 2022 was 2.2M, -69.69% growth from 2021.
- Inhibrx annual revenue for 2023 was 1.8M, -17.88% growth from 2022.
On this page
Zippi applies for you, and finds you a job.
Inhibrx historical revenue
Inhibrx's peak revenue was $12.9M in 2020. The peak quarterly revenue was $5.9M in 2020(q3).
Inhibrx's revenue increased from $13.2m in 2019 to $1.8M currently. That's a -80.17% change in annual revenue.
Inhibrx annual revenue
Inhibrx annual revenue over time
| Fiscal year / year | Inhibrx revenue |
|---|---|
| 2019 | $9.1M |
| 2020 | $12.9M |
| 2021 | $7.2M |
| 2022 | $2.2M |
| 2023 | $1.8M |
How accurately did Inhibrx's revenue projections match actual performance?
Inhibrx annual growth
Inhibrx saw the greatest revenue growth in 2020, when revenue increased by -2.44%.
Inhibrx had the lowest revenue growth in 2022, when revenue changed by -69.69%.
Inhibrx annual growth rate over time
| Year | Inhibrx growth |
|---|---|
| 2020 | 42%↑ |
| 2021 | -44%↓ |
| 2022 | -70%↓ |
| 2023 | -18%↓ |
Inhibrx quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Inhibrx quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | - | - | $5.9M | $2.8M |
| 2021 | $889,000 | $954,000 | $2.5M | $2.9M |
| 2022 | $929,000 | $711,000 | $278,000 | $274,000 |
| 2023 | $17,000 | $30,000 | $119,000 | $1.6M |
Inhibrx jobs nearby
Do you work at Inhibrx?
Is Inhibrx transparent about its revenue structure?
Inhibrx financial information
| CEO | Mark Paul Lappe |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 80 |
| Date Founded | 2010 |
| Headquarters | San Diego, California |
| Number of Locations | 1 |
| Revenue | $1.8M |
| Net Income | -$145,226,000 |
| Tax Rate | -0.0% |
| Total Assets | $290,875,000 |
| Ticker | INBX |
Inhibrx jobs you might like
Inhibrx financing
Inhibrx received early financing of $6.0M on 2017-12-31.
| Series | Round size | Date |
|---|---|---|
| Grant | $6M | 12/2017 |
| Series Unknown | $3.6M | 05/2018 |
| Convertible Note | $40M | 05/2019 |
Inhibrx investors
| Investors | Security type |
|---|---|
| CARB-X | Grant |
| Viking Global Investors | Convertible Note |
| Alexandria Venture | Convertible Note |
| Lilly Asia Ventures | Convertible Note |
| WuXi Biologics | Convertible Note |
| ArrowMark Partners | Convertible Note |
| RA Capital Management | Convertible Note |
Inhibrx competitors
Inhibrx's top competitor, Seres Therapeutics, earned an annual revenue of $144.9M.
Inhibrx's smallest competitor is GT Biopharma with revenue of $27.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Cara Therapeutics | - | $7.1M | 84 | - |
| GT Biopharma | - | $27,000 | 2 | - |
| Gemini Therapeutics | - | $1.6M | 36 | - |
| Seres Therapeutics | - | $144.9M | 145 | - |
| Cyclerion | - | $2.0M | 175 | - |
| Applied Molecular Transport | - | $8.3M | 80 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| Aclaris Therapeutics | - | $18.7M | 60 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Inhibrx highest paying jobs
Zippia gives an in-depth look into the details of Inhibrx, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Inhibrx. The employee data is based on information from people who have self-reported their past or current employments at Inhibrx. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Inhibrx. The data presented on this page does not represent the view of Inhibrx and its employees or that of Zippia.
Inhibrx may also be known as or be related to INHIBRX, INC., Inhibrx, Inhibrx Inc, Inhibrx LLC and Inhibrx, Inc.